13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
70 檔
13.5%
According to the latest 13F quarterly dataset, Silverarc Capital Management, LLC managed an equity portfolio of $962.2M at the end of Q2 2024, spanning 70 distinct U.S. exchange-listed positions.
During Q2 2024, Silverarc Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 8.71% | — | +10.13% | |
| 2 | NUVL | Nuvalent Inc-a | Stock-Other | 8.33% | -3.71% | EXIT | |
| 3 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 4.99% | — | +5.81% | |
| 4 | URGN | UroGen Pharma Ltd. | Stock-Other | 4.36% | +2.22% | +116.68% | |
| 5 | ERAS | Erasca Inc | Stock-Other | 4.35% | -0.66% | +3392.12% | |
| 6 | ✓ | Insmed Inc | Stock-Other | 3.95% | — | — | |
| 7 | MORFUSD | Morphic Holding Inc | Stock-Other | 3.91% | — | +0.48% | |
| 8 | AKRO | Akero Therapeutics Inc | Stock-Other | 3.46% | — | +56.29% | |
| 9 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.27% | -0.58% | EXIT | |
| 10 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.11% | — | +452.60% | |
| 11 | PSTXUSD | Poseida Therapeutics Inc | Stock-Other | 2.49% | — | +0.32% | |
| 12 | COGT | Cogent Biosciences Inc | Stock-Other | 2.40% | -0.01% | +16.36% | |
| 13 | INSM | Insmed Inc | Stock-Healthcare | 2.21% | -0.22% | +23.22% | |
| 14 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.06% | — | — | |
| 15 | ELUT | Elutia Inc | Stock-Other | 1.88% | -0.05% | +1940.70% | |
| 16 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.84% | — | +439.37% | |
| 17 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.79% | -0.59% | -3.34% | |
| 18 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.79% | +0.64% | — | |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.79% | +0.87% | +0.48% | |
| 20 | CCCC | C4 Therapeutics Inc | Stock-Other | 1.57% | +0.96% | +0.48% | |
| 21 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.57% | — | — | |
| 22 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.56% | -5.91% | EXIT | |
| 23 | VCYT | Veracyte Inc | Stock-Other | 1.44% | +1.35% | +0.53% | |
| 24 | ABVX | Abivax Sa-adr | Stock-Other | 1.42% | -1.09% | +507.73% | |
| 25 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.40% | — | +6.12% | |
| 26 | ✓ | Adc Therapeutics SA | Stock-Other | 1.32% | — | +252.89% | |
| 27 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.21% | — | — | |
| 28 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.19% | — | -15.77% | |
| 29 | GOSS | Gossamer Bio Inc | Stock-Other | 1.17% | — | -10.28% | |
| 30 | TELA | Tela Bio Inc | Stock-Other | 1.11% | +0.03% | +28.72% | |
| 31 | IRON | Disc Medicine Inc | Stock-Other | 1.08% | -0.65% | — | |
| 32 | BIIB | Biogen Inc | Stock-Healthcare | 1.06% | +0.13% | — | |
| 33 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.04% | — | +122.83% | |
| 34 | GERN | Geron CORP | Stock-Other | 1.00% | — | +299.71% | |
| 35 | BHVN | Biohaven Ltd. | Stock-Other | 0.82% | — | — | |
| 36 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 0.78% | — | — | |
| 37 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.66% | -0.06% | -64.68% | |
| 38 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.65% | — | +605.16% | |
| 39 | ✓ | Biodesix Inc | Stock-Other | 0.65% | — | — | |
| 40 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.64% | — | — | |
| 41 | SLDB | Solid Biosciences Inc | Stock-Other | 0.63% | +0.69% | NEW | |
| 42 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.61% | — | — | |
| 43 | CERS | Cerus CORP | Stock-Other | 0.61% | +0.46% | — | |
| 44 | ✓ | Compugen LTD | Stock-Other | 0.59% | -0.01% | +50.11% | |
| 45 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.59% | +0.69% | — | |
| 46 | KOD | Kodiak Sciences Inc | Stock-Other | 0.59% | -1.65% | -14.27% | |
| 47 | JSPR | Jasper Therapeutics Inc | Stock-Other | 0.59% | — | — | |
| 48 | ✓ | Engene Holdings Inc | Stock-Other | 0.59% | — | — | |
| 49 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.58% | — | — | |
| 50 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.58% | -0.33% | EXIT |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 70 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, NUVL, RNAGBP) accounted for 13.5% of total reported equity market value during Q2 2024.
During Q2 2024, Silverarc Capital Management, LLC's top holdings by market value included MERUS N V (8.7%)、NUVL (8.3%)、RNAGBP (5.0%). The largest single position, MERUS N V, represented 8.7% of total portfolio value.
In Q2 2024, Silverarc Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.